Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syra HealthSYRA +4.63%12 Return-on-Tangible-Asset is 28.70% as of Mar. 2026. GuruFocus rates SYRA with a GF Score™ of 12/100 and a GF Value™ of $0.23 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 681 Healthcare Providers & Services companies, Syra Health ranks worse than 72.98% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Syra Health's annualizedNet Income for the quarter that ended in Mar. 2026 was $0.96 Mil. Syra Health's average total tangible assets for the quarter that ended in Mar. 2026 was $3.36 Mil. Therefore, Syra Health's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 28.70%.
The historical rank and industry rank for Syra Health's Return-on-Tangible-Asset or its related term are showing as below:
SYRA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -148.27 Med: -81.13 Max: -1.11
Current: -5.36
During the past 6 years, Syra Health's highest Return-on-Tangible-Asset was -1.11%. The lowest was -148.27%. And the median was -81.13%.
SYRA's Return-on-Tangible-Asset is ranked worse than 72.98% of 681
companies
in the Healthcare Providers & Services industry
Industry Median: 2.5
vs SYRA: -5.36
Syra Health (OTCPK:SYRA) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Syra Health Return-on-Tangible-Asset Related Terms
Syra Health Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Syra Health's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SYRA vs NIVF, BICX, HLYK: Return-on-Tangible-Asset Comparison
For the Medical Care Facilities subindustry, Syra Health's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syra Health Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Syra Health's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Syra Health's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 28.70% mean?
Syra Health (SYRA) has a Return-on-Tangible-Asset of 28.70% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Syra Health and its competitors. According to the industry distribution chart, Syra Health ranks #497 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 73%.
Is Syra Health's Return-on-Tangible-Asset too high?
Syra Health's current Return-on-Tangible-Asset is 28.70%. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.50. Syra Health's value of 28.70% is 1048% above this industry median. Based on the distribution chart, Syra Health ranks #497 out of 681 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Syra Health has a GF Score™ of 12/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Syra Health's Return-on-Tangible-Asset compare to NIVF and BICX?
According to the Healthcare Providers & Services industry distribution chart, Syra Health ranks #497 out of 681 companies for Return-on-Tangible-Asset. This places Syra Health in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.50. Syra Health's value of 28.70% is 1048% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.50, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syra Health's current Return-on-Tangible-Asset of 28.70% is 1048% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Syra Health and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syra Health's current Return-on-Tangible-Asset is 28.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syra Health stock overvalued right now?
Based on GuruFocus' analysis, Syra Health (SYRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.23, compared to a current price of $0.80 — trading 245.7% above its estimated fair value. The current Return-on-Tangible-Asset is 28.70% and 1048% above the Healthcare Providers & Services industry median of 2.50. Syra Health's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Syra Health (SYRA), the current Return-on-Tangible-Asset is 28.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syra Health (SYRA) Overvalued in 2026?
Based on GuruFocus' analysis, Syra Health stock appears to be overvalued.
The current stock price of $0.80 is trading 245.7% above its estimated GF Value™ of $0.23.
GuruFocus considers Syra Health to be Significantly Overvalued.
Key valuation signals for SYRA:
Return-on-Tangible-Asset: 28.70%
GF Value™: $0.23 vs. price of $0.80 (245.7% above fair value)
Industry Position: 1048% above the Healthcare Providers & Services median (#497 of 681)
No single metric tells the full story. See the SYRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syra Health Corp is an integrated healthcare solutions company serving government and commercial healthcare organizations. It delivers end-to-end capabilities across population health, behavioral and mental health, digital health, health education and training, and healthcare workforce development and staffing. The various services offered by the company include Syrenity, a mental health application providing preventative care and interventions for behavioral and mental health conditions; SyraBot, a chatbot offering members access to necessary information via the firm's AI-powered customer support chat system; CarePlus, an electronic medical records solution designed for small to mid-sized healthcare organizations; and patient engagement and education services, among others.
12GF Score
Get the complete analysis for SYRA
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYRA has been successfully added to your 
